Phaseline

Companies › Guangdong Hengqin Novagains Biopharmaceutical

Guangdong Hengqin Novagains Biopharmaceutical: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Metabolic and endocrine.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
F-02-2-Na–Phase 1Hyperuricemia With or Without Gout–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07346027F-02-2-NaPhase 1Hyperuricemia With or Without GoutMetabolic and endocrineAug 2026

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.